Australia's most trusted
source of pharma news
Posted 16 October 2025 PM
A strategic supplier relationship between Aussie cell therapy company Chimeric Therapeutics and the Viral Vector Manufacturing Facility (VVMF) has been hailed as a win for local advanced therapy capabilities.
Under a freshly inked Letter Of Intent, VVMF will support process development, technology transfer, and GMP manufacturing of Lentiviral vectors for Chimeric’s clinical stage chimeric antigen receptor (CAR-T) program. Viral vectors are a critical component in the production of CAR-T therapies, which are transforming cancer treatment globally.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.